<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604419</url>
  </required_header>
  <id_info>
    <org_study_id>PB119202</org_study_id>
    <nct_id>NCT03604419</nct_id>
  </id_info>
  <brief_title>Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 to Patients With Type 2 Diabetes Mellitus (T2DM) Not Well-controlled by Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PegBio Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PegBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, multicenter study to evaluate the efficacy and safety of twelve once weekly&#xD;
      subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not&#xD;
      well-controlled by metformin mono therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel dose cohort,&#xD;
      multiple dose study to evaluate the efficacy, safety, and tolerability of different doses of&#xD;
      PB-119 to patients with T2DM not well-controlled by metformin monotherapy. Patients will be&#xD;
      assessed for eligibility over a 2 week screening period prior to a 4-week run-in period and a&#xD;
      12-week double-blind treatment period.A phase 2, multicenter, randomized, double-blind,&#xD;
      placebo-controlled, parallel dose cohort study to evaluate the efficacy and safety of twelve&#xD;
      once weekly subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not&#xD;
      well-controlled by metformin monotherapy The eligible patients will be randomized to 1 of 3&#xD;
      dose cohorts (A, B, or C). Each patient will subsequently be randomized within the designated&#xD;
      cohort to 1) active drug or placebo at a 3:1 active drug:placebo ratio and 2) exclusion from&#xD;
      or inclusion in the pharmacokinetic (PK) blood sample collection subgroup at a 3:1&#xD;
      excluded:included ratio&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline value of HbA1c will be compared between treatments</measure>
    <time_frame>From Baseline to end of treatment (up to Week 12)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline value of Fasting Plasma Glucose at Weeks 2, 4, 8, and 12</measure>
    <time_frame>From Baseline to end of treatment (up to Week 12)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>PB-119 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 150 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 200 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 100 μg+ Glucophage®</intervention_name>
    <description>Each patient will subsequently be randomized within the designated cohort to active drug or placebo</description>
    <arm_group_label>PB-119 150 μg</arm_group_label>
    <arm_group_label>PB-119 200 μg</arm_group_label>
    <arm_group_label>PB-119 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 150 μg+ Glucophage®</intervention_name>
    <description>Each patient will subsequently be randomized within the designated cohort to active drug or placebo</description>
    <arm_group_label>PB-119 100 μg</arm_group_label>
    <arm_group_label>PB-119 200 μg</arm_group_label>
    <arm_group_label>PB-119 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 200 μg+ Glucophage®</intervention_name>
    <description>Each patient will subsequently be randomized within the designated cohort to active drug or placebo</description>
    <arm_group_label>PB-119 100 μg</arm_group_label>
    <arm_group_label>PB-119 150 μg</arm_group_label>
    <arm_group_label>PB-119 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB-119 placebo + Glucophage®</intervention_name>
    <description>Each patient will subsequently be randomized within the designated cohort to active drug or placebo</description>
    <arm_group_label>PB-119 100 μg</arm_group_label>
    <arm_group_label>PB-119 150 μg</arm_group_label>
    <arm_group_label>PB-119 200 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients in whom T2DM has been diagnosed according to 2018 American Diabetes&#xD;
             Association T2DM diagnostic criteria, have made lifestyle modifications (ie, diet and&#xD;
             exercise) for at least 3 months prior to Screening, and have been taking metformin for&#xD;
             at least 3 months before Screening with a stable dosage for at least 8 weeks (stable&#xD;
             dosage is defined as metformin dosage ≥1500 mg/day or maximum tolerated dose).&#xD;
&#xD;
          2. Males and/or females between the ages of ≥18 and ≤70 years at Screening&#xD;
&#xD;
          3. HbA1c ≥7.5% and ≤11% at Screening and at Week -1, Visit 3.1;&#xD;
&#xD;
          4. FPG ≥126 and ≤240 mg/dL (≥7.0 and ≤13.3 mmol/L) at Screening and at Week -1, Visit&#xD;
             3.1;&#xD;
&#xD;
          5. Body mass index (BMI) ≥18.5 and ≤40.0 kg/m2 at Screening, with inclusion of patients&#xD;
             with BMIs at the lower end of the range enrolled into the study to enable comparisons&#xD;
             across BMI range;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history or current diagnosis of:&#xD;
&#xD;
               1. Type 1 diabetes mellitus, diabetes caused by pancreas injury or by other diseases&#xD;
                  (like acromegaly or Cushing syndrome);&#xD;
&#xD;
               2. Diabetes acute complication, like ketoacidosis or hyperosmolar coma;&#xD;
&#xD;
               3. Diagnosed proliferative retinopathy;&#xD;
&#xD;
               4. 3 instances of severe hypoglycemia (events during which the patient required the&#xD;
                  assistance of another person to actively administer carbohydrate, glucagon, or&#xD;
                  other resuscitative actions; episodes may be associated with sufficient&#xD;
                  neuroglycopenia to have induced seizure or coma) in the 6 months prior to&#xD;
                  Screening;&#xD;
&#xD;
               5. Significant vascular disease;&#xD;
&#xD;
          2. Current/ongoing diagnosis of any type of malignant tumor or evidence of recurrence in&#xD;
             the 6 months prior to Screening (patients who have been stable for ≥6 months or those&#xD;
             who have had basal or squamous cell skin cancers removed and have no evidence of&#xD;
             recurrence will not be excluded). Patients with a medical history of any other type of&#xD;
             cancer in the last 5 years prior to Screening will be excluded;&#xD;
&#xD;
          3. Severe cardiovascular diseases occurring within 6 months prior to Screening (eg,&#xD;
             congestive heart disease, myocardial infarction, acute coronary syndrome, apoplexy,&#xD;
             transient ischemic attack);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

